What is the current size and annual growth rate of the granulomatosis with polyangiitis treatment market?
The granulomatosis with polyangiitis treatment market size has grown strongly in recent years. It will grow from $2.36 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the growing need for the drugs, the growing number of clinical trials, the rising demand for effective treatment, the growing emphasis on personalized medicine, and increasing diagnosis rates of the disorder.
The granulomatosis with polyangiitis treatment market size is expected to see strong growth in the next few years. It will grow to $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to the increasing prevalence of autoimmune diseases, rising prevalence of granulomatosis, increase in the incidences of polyangiitis, and rise in the prevalence of immunological disorders. Major trends in the forecast period include advancements in drug development, developments in healthcare, advancements in diagnostic techniques, advancements in treatment options, and the development of biologics and biosimilars.
Get Your Free Sample of The Global Granulomatosis With Polyangiitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21196&type=smp
Which major factors have contributed to the expansion of the granulomatosis with polyangiitis treatment market?
The increasing prevalence of autoimmune diseases is expected to propel the growth of the granulomatosis with polyangiitis treatment market going forward. Autoimmune diseases occur when the body’s immune system mistakenly attacks its healthy cells and tissues, leading to inflammation and damage in various organs. The increasing prevalence of autoimmune diseases is due to environmental triggers (such as infections, chemicals, or pollutants) and lifestyle changes. Granulomatosis with polyangiitis treatment is helpful for autoimmune diseases by utilizing immunosuppressive therapies such as corticosteroids and cyclophosphamide, which help control inflammation and prevent organ damage, making early intervention and tailored treatment crucial for managing other autoimmune conditions with similar mechanisms. For instance, in June 2023, according to a report published by the Office for National Statistics, a UK-based government department, the global population of people with multiple sclerosis (MS) (an autoimmune disease) in 2023 was 2.9 million, up from 2.8 million in 2022. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the granulomatosis with polyangiitis treatment market.
How is the granulomatosis with polyangiitis treatment market segmented?
The granulomatosis with polyangiitis treatment market covered in this report is segmented –
1) By Drug Type: Steroids, Immunosuppressant, Other Drug Types
2) By Treatment Type: Immunosuppressants, Corticosteroids
3) By Route Of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab
3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/granulomatosis-with-polyangiitis-treatment-global-market-report
Who are the top competitors in the granulomatosis with polyangiitis treatment market?
Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech Inc., Incyte Corporation, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ChemoCentryx Inc., Medac Pharma Inc., InflaRx GmbH
Which key trends are expected to influence the granulomatosis with polyangiitis treatment market in the coming years?
Major companies operating in the granulomatosis with polyangiitis treatment market are focusing on developing innovative products, such as oral corticosteroids, to offer patients more effective treatment options that improve disease management while minimizing the long-term side effects of steroid use. Oral corticosteroids are a medication that reduces inflammation and suppresses the immune system. They are commonly used to treat allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a UK-based pharmaceutical company, announced Fasenra (bevacizumab) had been approved in the European Union, a Europe-based political and economic union of European countries, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The approval follows positive results from the MANDARA Phase III trial, demonstrating the efficacy of Fasenra in achieving remission and reducing reliance on oral corticosteroids in EGPA patients.
Which regional trends are influencing the granulomatosis with polyangiitis treatment market, and which area dominates the industry?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Granulomatosis With Polyangiitis Treatment Market Report 2025 Offer?
The granulomatosis with polyangiitis treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Granulomatosis with Polyangiitis (GPA) treatment involves the use of medications to control inflammation, suppress the immune system, and prevent organ damage. Granulomatosis with polyangiitis (GPA) is a rare autoimmune disorder causing inflammation of small to medium blood vessels, leading to restricted blood flow and tissue damage, particularly in the respiratory tract and kidneys. Treatment primarily involves immunosuppressive therapies, such as corticosteroids and biologics, to reduce inflammation and prevent organ damage.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21196
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
